Podcasts about Genomics

Discipline in genetics

  • 1,526PODCASTS
  • 3,216EPISODES
  • 40mAVG DURATION
  • 5WEEKLY NEW EPISODES
  • May 27, 2025LATEST
Genomics

POPULARITY

20172018201920202021202220232024

Categories



Best podcasts about Genomics

Show all podcasts related to genomics

Latest podcast episodes about Genomics

OffScrip with Matthew Zachary
Constellations and Cancer: A Storytelling Rebellion with Lisa Shufro

OffScrip with Matthew Zachary

Play Episode Listen Later May 27, 2025 40:11


EPISODE DESCRIPTIONLisa Shufro is the storyteller's storyteller. A musician turned innovation strategist, TEDMed curator, and unapologetic truth-teller, Lisa doesn't just craft narratives—she engineers constellations out of chaos. We go way back to the early TEDMed days, where she taught doctors, scientists, and technocrats how not to bore an audience to death. In this episode, we talk about how storytelling in healthcare has been weaponized, misunderstood, misused, and still holds the power to change lives—if done right. Lisa challenges the idea that storytelling should be persuasive and instead argues it should be connective. We get into AI, the myth of objectivity, musical scars, Richard Simmons, the Vegas healthcare experiment, and the real reason your startup pitch is still trash. If you've ever been told to “just tell your story,” this episode is the permission slip to do it your way. With a bow, not a violin.RELATED LINKSLisa Shufro's WebsiteLinkedInSuper Curious ArchiveEight Principles for Storytelling in InnovationStoryCorps InterviewCoursera Instructor ProfileWhatMatters ProjectFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

NYU Langone Insights on Psychiatry
The Next Big Breakthrough

NYU Langone Insights on Psychiatry

Play Episode Listen Later May 21, 2025 43:30 Transcription Available


What if mental health care worked more like cancer treatment—tailored to the individual, informed by biology, and driven by data? Charles Marmar, MD, Chair of Psychiatry at NYU Grossman School of Medicine, takes us through the latest advances in precision psychiatry. From brain imaging to digital phenotyping, Dr. Marmar outlines the tools shaping a future where treatment is fully customized. He also shares stories from the front lines: a patient whose depression was treated with the help of a brain biopsy, why PTSD and depression aren't one-size-fits-all, and how quantum computing could radically accelerate psychiatric research.

OffScrip with Matthew Zachary
Dancing Through the Wreckage: Sally Wolf

OffScrip with Matthew Zachary

Play Episode Listen Later May 20, 2025 39:59


What happens when you blend the soul of Mr. Rogers, the boldness of RuPaul, and just a pinch of Carrie Bradshaw? You get Sally Wolf.She's a Harvard and Stanford powerhouse who ditched corporate media to help people actually flourish at work and in life—because cancer kicked her ass and she kicked it back, with a pole dance routine on Netflix for good measure.In this episode, we unpack what it means to live (really live) with metastatic breast cancer. We talk about the toxic PR machine behind "pink ribbon" cancer, how the healthcare system gaslights survivors when treatment ends, and why spreadsheets and dance classes saved her sanity. Sally doesn't just survive. She rewrites the script, calls out the BS, and shows up in full color.If you've ever asked “Why me?”—or refused to—this one's for you.RELATED LINKS:Sally Wolf's WebsiteLinkedInInstagramCosmopolitan Essay: "What It's Like to Have the 'Good' Cancer"Oprah Daily Article: "Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis"Allure Photo ShootThe Story of Our Trauma PodcastFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Beginner's Mind
EP 158 - Rafael Rosengarten: Why 90% of Cancer Drugs Fail — and the Radical AI Fix You've Never Heard Of

Beginner's Mind

Play Episode Listen Later May 16, 2025 120:48 Transcription Available


 Most cancer drugs fail. Not because the science is wrong—because we're solving the wrong problems.The cost? Over $2 billion per failure. And for the patient waiting on a miracle—there's no second chance.Behind the headlines of “precision medicine,” there's a deeper story nobody's telling. Until now. 

NYU Abu Dhabi Institute
Creative Convergence: The Role of Artists in Expanding Scientific Inquiry and UAE's Vision for Innovation

NYU Abu Dhabi Institute

Play Episode Listen Later May 15, 2025 52:53


This panel explores how integrating art, science and engineering fosters innovation, broadens perspectives, and drives societal contributions. In the UAE's cultural and scientific landscape, interdisciplinary collaboration is crucial to engage the public, inspire creativity, and support the nation's long-term goals in education and research. Panelists Iyad Rahwan, Director of the Max Planck Institute for Human Development, Berlin Stephanie Rosenthal, Director of the Guggenheim Abu Dhabi Project Henry Tan, Artist in Residence at the NYU Abu Dhabi Center for Genomics and Systems Biology Moderated by Maya Allison, NYU Abu Dhabi Chief Curator and Galleries Executive Director In collaboration with Center for Genomics and Systems Biology

Pharma and BioTech Daily
Pharma and Biotech Daily: Restructuring, Innovation Opportunities, and Industry Updates

Pharma and BioTech Daily

Play Episode Listen Later May 14, 2025 1:10


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Bayer has announced a restructuring that will result in 2,000 job cuts and a reduction in management layers. CEO Bill Anderson believes Trump's most favored nations policy could provide an opportunity for European countries to contribute more to biopharma innovation. Galapagos has abandoned plans for a spinout and cell therapy, causing a stir in the industry. Trump's most favored nation policy has led to a sell-off of PBMs, but analysts believe it may not have a significant impact without further congressional action. Sino Biological offers solutions for autoimmune diseases, with reagents for nearly 50 different conditions. In other news, CMS is preparing for a new cycle of drug negotiations, Azafaros has raised $150 million for rare neuro-metabolic diseases, and Roche's Genentech is investing $700 million in a North Carolina plant. 10x Genomics has cut 8% of its workforce, and there are upcoming webinars on biotech downturns and AI in life science R&D. Job opportunities include positions at 4D Molecular Therapeutics, Takeda, and Regeneron Pharmaceuticals.

Speaking of Mol Bio
The hidden language of RNA – how epigenetics is shaping medicine

Speaking of Mol Bio

Play Episode Listen Later May 14, 2025 31:51


This episode teaches that innovation is born at the intersection of curiosity and persistence. Dr. Gudrun Stengel, co-founder and CEO of Alida Biosciences, reveals how her startup is transforming the landscape of RNA research through a novel technology called proximity barcoding. Dr. Stengel's story exemplifies the power of entrepreneurial spirit in driving scientific discovery, offering a glimpse into how one idea can reshape an entire field.At Alida Biosciences, Dr. Stengel and her team are pioneering new tools for detecting RNA modifications, a largely unexplored realm of epigenetics. Using their proximity barcoding platform, researchers can read multiple RNA modifications simultaneously, uncovering potential biomarkers and therapeutic targets for diseases like cancer, Alzheimer's, and diabetes. This technology bridges a critical gap in multiomics, allowing scientists to dive deeper into how epigenetic changes influence gene expression and cellular behavior.Beyond the lab, Dr. Stengel shares her experience as a first-time founder, balancing scientific rigor with startup life. From managing a team to fundraising, her journey underscores the importance of resilience, optimism, and maintaining a long-term vision. She also offers valuable advice for budding scientists, encouraging them to embrace challenges and remain persistent in the face of setbacks. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

Biohacker Babes Podcast
Parasites, Sleep Deprivation & Nervous System Support l Highlights from Season 12 Guests, Bioharmonizing for Women, Hashimoto's Thyroiditis, PEMF Technology, Fertility Support & Genomics for Precision Medicine

Biohacker Babes Podcast

Play Episode Listen Later May 12, 2025 45:08


In this episode, we delve into our latest biohacking experiments and share insights from recent interviews with leading experts in the health and wellness space. We discuss the concept of "bioharmonizing" with Dr. Melissa Sonners, a functional medicine approach to thyroid conditions like Hashimoto's with Dr. Heather Stone, PEMF technology with Mike & Alyssa from Align Mat, the role of genomics in precision medicine with Dr. Matt Dawson from Wild Health, and the emotional aspects of fertility with Beth Gulotta from Quiet the Clock. Join us for this fun and inspiring conversation!SHOW NOTES:0:39 Welcome to the show!2:57 Renee's current sleep experiment8:59 Cell detox & parasite cleansing12:02 Most recent podcast recap12:57 Ep 289: Dr Melissa Sonners14:21 Getting over people-pleasing16:59 Ep 290: Dr Heather Stone18:03 Gaslighting from doctors20:40 Missing nutrition link for Hashimoto's22:56 Ep 291: Mike & Alyssa of Align Mat24:25 All the PEMF mats we've tried28:10 *PIQUE TEA*30:21 *ALIGN MAT*31:58 Ep 292: Wild Health34:32 Are higher fat diets for you?37:14 Ep 293: Beth Gulotta40:31 Importance of getting into parasympathetic42:23 Noticing the ‘Red Ferrari'43:47 Upcoming EventsRESOURCES:Onera At-Home Sleep StudyALIGN MAT - Save $250 with code: BIOHACKERBABESPIQUE TEABe Inspired Mama - Dr. Melissa SonnersWild HealthQuiet the Clock - Beth GulottaUltimate Wellness in Miami - Save with code: BIOHACKERBABESHealthspan SummitHack Your Health in Tampa - Save with code: BIOHACKERBABESOur Sponsors:* Check out Puori: https://Puori.com/BIOHACKERBABESSupport this podcast at — https://redcircle.com/biohacker-babes-podcast/donationsAdvertising Inquiries: https://redcircle.com/brands

I Am Refocused Podcast Show
Unhooked: Breaking Cycles, Building Discipline w/ Jeremy Lipkowitz

I Am Refocused Podcast Show

Play Episode Listen Later May 3, 2025 32:25


In this transformative episode, we sit down with Jeremy Lipkowitz—a former Buddhist monk, meditation teacher, and ICF-certified executive coach—who now helps high-achieving men break free from compulsive behaviors like porn addiction and reclaim lives of integrity, focus, and deep fulfillment. Jeremy opens up about his personal journey from academia to the monastery, how shame and addiction nearly consumed him, and what it truly takes to become unhooked from self-sabotaging habits. We dive into the neuroscience of addiction, the role of emotional intelligence in healing, and the daily disciplines that create lasting change. Whether you're battling compulsive behavior or simply seeking a life of greater clarity and purpose, this conversation will challenge, ground, and inspire you.Jeremy Lipkowitz is a former Buddhist monk turned executive coach who helps high-performing men break free from compulsive behaviors and live with greater clarity, integrity, and emotional resilience. With degrees in Genetics & Genomics and a deep background in mindfulness and meditation—spanning over 13 years and hundreds of days in silent retreat—Jeremy blends science and spirituality to guide lasting transformation. As the founder of Unhooked Academy and host of the Unhooked Podcast, he is a leading voice in destigmatizing porn addiction and empowering men to build lives rooted in purpose, discipline, and freedom.https://www.jeremylipkowitz.com/Become a supporter of this podcast: https://www.spreaker.com/podcast/i-am-refocused-radio--2671113/support.

Rational Wellness Podcast
Kidney Care with Peptides with Dr. Robin Rose: Rational Wellness Podcast 408

Rational Wellness Podcast

Play Episode Listen Later May 2, 2025 62:24


View the Show Notes For This Episode Dr. Robin Rose discusses Kidney Care with Peptides with Dr. Ben Weitz. [If you enjoy this podcast, please give us a rating and review on Apple Podcasts, so more people will find The Rational Wellness Podcast. Also check out the video version on my WeitzChiro YouTube page.]   Podcast Highlights In this episode of the Rational Wellness Podcast, Dr. Ben Weitz hosts Dr. Robin Rose to discuss crucial insights into kidney health. They explore the kidney's functions, including filtering blood, regulating electrolytes, and converting vitamin D. The conversation delves into chronic kidney disease, highlighting that symptoms can arise even in stage two when GFR drops below 60. Dr. Rose emphasizes the importance of early detection and intervention, discussing concepts such as uremic dysbiosis, endothelial damage, leaky gut, and the impact of toxins. They also touch on natural and supplemental approaches to support kidney health, like using bio-regulator peptides, nutritional therapy, and plant-based diets. Additionally, Dr. Rose shares her personal experience with kidney cancer and the insights she gained during her journey to recovery.   00:26 Understanding Kidney Functions and Chronic Kidney Disease 02:10 In-Depth Discussion with Dr. Robin Rose 02:34 The Complexities of Kidney Health 04:28 Kidney and Gut Health Connection 04:54 Challenges in Measuring Kidney Function 08:48 Managing Kidney Health Through Diet and Lifestyle 28:43 Nutritional Supplements for Kidney Health 33:23 Butyrate and Gut Health 33:56 Cardiovascular Markers and Genomics 34:59 Kidney Health Botanicals 37:31 Peptides and Their Benefits 43:06 Bio-Regulator Peptides 51:31 Personal Kidney Health Journey 52:48 Hydration and Herbal Teas 54:40 Final Thoughts and Resources     ________________________________________________________________________________________________________ Dr. Robin Rose is a Medical Doctor and an expert at supporting kidney health using a wholistic approach and peptides.  She has recently published a book, Renology Peptides: Kidney Success with Bioregulator Peptides. Renology Peptides is a comprehensive clinical volume that presents an evidence-guided scholarly tool to deepen understanding of regenerative kidney medicine and bioregulator peptides. Her website is Renology is Kidney Success.    Dr. Ben Weitz is available for Functional Nutrition consultations specializing in Functional Gastrointestinal Disorders like IBS/SIBO and Reflux and also Cardiometabolic Risk Factors like elevated lipids, high blood sugar, and high blood pressure.  Dr. Weitz has also successfully helped many patients with managing their weight and improving their athletic performance, as well as sports chiropractic work by calling his Santa Monica office 310-395-3111.

The Genetics Podcast
EP 185: From newborn screening to lifelong data in an evolving genomics landscape with Madhuri Hegde of Revvity

The Genetics Podcast

Play Episode Listen Later May 1, 2025 40:44


This week on The Genetics Podcast, Patrick is joined by Madhuri Hegde, SVP and Chief Scientific Officer of Revvity. They discuss Revvity's advances in ultra-rapid clinical-grade sequencing, opportunities, challenges, and global inequities in newborn screening, and the dilemma of resequencing versus long-term data storage.Show Notes: 0:00 Intro to The Genetics Podcast00:59 Welcome to Madhuri01:52 Rebranding Revvity as a healthcare company02:51 Advancements in sequencing and Revvity's projects, including newborn screening tests and clinical ultra-rapid sequencing12:29 Opportunities and challenges for newborn sequencing and global inequity in access17:46 Price of sequencing and data storage versus resequencing considerations21:10 Complexities and nuances of genomic data interpretation23:28 Rethinking data portability and storage across the lifespan26:00 Understanding penetrance and population genetics through lifelong sequencing27:36 Scaling genetic counseling to match advancements and the potential value of chatbots32:45 The promise of proteomics and translating Olink data to the clinic 34:31 Implementing polygenic risk scores in clinical management  37:12 Transitioning from academia to industry and insights into product development38:37 Closing remarksFind out moreRevvity (https://www.revvity.com/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link

The Oncology Podcast
Breaking Down Silos: How MPCCC is Transforming Cancer Care

The Oncology Podcast

Play Episode Listen Later May 1, 2025 34:25 Transcription Available


Send us a textWelcome to Episode 29 of The Oncology Podcast's Experts On Point series, brought to you by The Oncology Network. Hosted by Rachael Babin.How do we tackle inequities in cancer care? What role do collaborative networks play in ensuring better outcomes for patients and their families? And how can molecular tumour boards bridge the gap for those outside metropolitan areas, giving them access to life-saving treatments and clinical trials?To explore these critical questions, our Host Rachael Babin is joined by Professor Mark Shackleton—Director of Oncology at Alfred Health, Professor of Oncology at Monash University, Chair of Melanoma and Skin Cancer Trials Ltd, and Co-Director of the Monash Partners Comprehensive Cancer Consortium (MPCCC).The Monash Partners Comprehensive Cancer Consortium (MPCCC) is transforming cancer care by creating networks that ensure equitable access to precision oncology across Victoria, regardless of a patient's location.Did You Know?• The MPCCC Fellowship program embeds early-career oncologists in partner hospitals to build expertise and connections• The Precision Oncology Program has processed over 1,000 patient referrals• 20% of referred patients receive recommendations for targeted therapies matched to their cancer's molecular profile• 5% of patients connected to clinical trials they wouldn't otherwise access• Regular molecular tumour boards discuss 5-10 cases per session• MPCCC has delivered a significant increase in regional cancer patient referrals, especially from GippslandVisit our website for information on the simple referral process through the Omico CaSP program and access this incredible resource for your patients. So, let's dive into the groundbreaking work being done to break down barriers and expand access to precision oncology.We hope you enjoy listening.For news and podcast updates subscribe to The Oncology Newsletter,  a free weekly publication for healthcare professionals with an interest in oncology. Click here to subscribe.PART OF THE ONCOLOGY NETWORK... Join Us

Na Synapsach
#genetics: what can we learn from ancient genomics? | Prof. Eske Willerslev

Na Synapsach

Play Episode Listen Later Apr 28, 2025 18:03


At the recent Interdisciplinary Scientific Seminar held at the Wrocław University of Science and Technology, participants had the opportunity and the pleasure to learn more about ancient genomes. Why are we studying them? What is environmental DNA? How can it be used? What information can such research provide us as humans? We invite you to listen to an interview with Prof. Eske Willerslev - an evolutionary geneticist - and discover that scientific research can be as fascinating as exploring Siberia.Feel free to explore the topic with Magdalena Filipow

Lab Rats to Unicorns
Building Biotech at the Interface: Geoff Duyk on Genomics, Platforms, and Grove Biopharma_e.67

Lab Rats to Unicorns

Play Episode Listen Later Apr 24, 2025 83:34


In this episode of Lab Rats to Unicorns, host John Flavin speaks with Dr. Geoff Duyk, co-founder and CEO of Grove Biopharma. Geoff brings over 35 years of experience across academia, biotech leadership, and venture capital. From his early work in human genetics at UCSF to co-founding Millennium Pharmaceuticals and leading R&D at Exelixis, Geoff unpacks the evolution of biotech from the 1970s to today. This conversation comes on the heels of Grove's massive $30M Series A. Geoff shares the story behind Grove Biopharma's founding, born from a collaboration between a Northwestern chemist, a green chemistry innovator, and himself—culminating in a startup focused on intracellular targets using novel protein-mimetic polymers. Geoff also reflects on the infrastructure and cultural foundations that make biotech innovation possible, from the NIH's visionary investments to the importance of people, timing, and place. Learn how Grove is challenging the limits of drug design with a new class of molecules that behave like antibodies but operate inside cells—unlocking new frontiers in cancer and beyond.

Slice of Healthcare
#492 - Peter Donnelly, CEO & Co-Founder at Genomics

Slice of Healthcare

Play Episode Listen Later Apr 23, 2025 21:50


Join us on the latest episode, hosted by Jared S. Taylor!Our Guest: Peter Donnelly, CEO & Co-Founder at Genomics.What you'll get out of this episode:Genomics' Mission: Founded in 2014, Genomics is bridging cutting-edge genetic research with real-world healthcare solutions.Actionable Insights: Advances now allow actionable health insights for ~70% of people via genetic testing.Strategic Partnerships: Collaborations with companies like Vertex and GSK use genetics to improve drug targeting and trial outcomes.Insurance Innovation: Life insurers are early adopters of genetics to promote longevity and healthier lives.The Future Is Now: With global health systems under pressure, predictive genomics is primed to shift care from treatment to prevention.To learn more about Genomics:Website: http://www.genomics.com/ LinkedIn: https://www.linkedin.com/company/genomics-ltd/Our sponsors for this episode are:Sage Growth Partners https://www.sage-growth.com/Quantum Health https://www.quantum-health.com/Show and Host's Socials:Slice of HealthcareLinkedIn: https://www.linkedin.com/company/sliceofhealthcare/Jared S TaylorLinkedIn: https://www.linkedin.com/in/jaredstaylor/WHAT IS SLICE OF HEALTHCARE?The go-to site for digital health executive/provider interviews, technology updates, and industry news. Listed to in 65+ countries.

STtalks
STtalks #272 - Sustainability is in our DNA: Earth Day with STgenetics®

STtalks

Play Episode Listen Later Apr 22, 2025 19:00


It's Earth Day and at STgenetics®, Sustainability is in our DNA! In this STtalks, we are joined by two leaders within our Research & Development team to share what global agricultural sustainability means to STgenetics® and what solutions we are providing to aid in the global environmental mission to become more sustainable and eco-friendly. From EcoFeed® to Ultraplus™ gender-sorted semen, STgenetics® has numerous tools and technology to help dairy and beef farmers successfully produce nutritious food sources to assure food security across the globe and to do so in a sustainable manner. Don't miss this globalized view on sustainability on Earth Day with STgenetics®!00:00 Introduction to Sustainability at STgenetics®00:47 Defining Sustainability in Agriculture02:10 Innovative Tools and Technologies03:07 Impact of Genomics and Gender Selection06:45 Precision Farming and Tropical Genetics11:03 Global Environmental Impact and Future Goals16:41 The Core of Sustainability at STgenetics®18:13 Conclusion and Earth Day Wishes

Business Leader
How Professor Sir Peter Donnelly went from brilliant statistician to entrepreneur

Business Leader

Play Episode Listen Later Apr 22, 2025 26:56


You haven't heard from anyone like Professor Sir Peter Donnelly before. He is a statistician, professor, a knight of the realm and an entrepreneur. Not only has he given a Ted Talk about statistics that has been viewed more than 1.5 million times, but he is now working on genetics tests that could save lives and change the world by helping people understand how predisposed they are to becoming obese or getting certain illnesses. Donnelly left his career in academia to become the co-founder and chief executive of Genomics, which is developing these genetic tests and is one of the fastest-growing businesses in the UK. But this may only be the start of its story... Hosted on Acast. See acast.com/privacy for more information.

Big Brains
Can Your DNA Predict Your Future?, with Dalton Conley

Big Brains

Play Episode Listen Later Apr 17, 2025 34:25


What if a single number, derived from your DNA, could predict your income, education level or even who you're likely to marry? In his new book “The Social Genome,” Princeton University sociologist Dalton Conley explores the science behind how our genes are shaping our society in ways that are both profound and unsettling.Conley explains how our genes, and the genes of those around us, are influencing our lives in ways we barely understand—from fertility clinics selecting embryos based on genetic traits to the rise of “genetic sorting” in everything from dating to zip codes. He also debunks the idea of nature versus nurture, revealing how deeply intertwined they truly are.Are we heading toward a future of genetically coded inequality? And what policies and conversations are urgently needed to ensure we don't cross the line from science into dystopia?

Translating Proteomics
Intro to Proteomics

Translating Proteomics

Play Episode Listen Later Apr 16, 2025 14:45


On this special episode of Translating Proteomics, Parag and Andreas break down the basics of proteomics — perfect for anyone with a background in molecular biology looking to get started in the field.Seasoned experts: We hope you can share this episode as a teaching tool or to inspire others to explore proteomics.Parag and Andreas cover the following questions in the episode, and links to additional Nautilus resources can be found below each question.What is proteomics?Blog post – What is proteomics? Techniques, applications, and methodsWhat are key questions proteomics can answer?Blog category – Applications of proteomicsWhy is it important to measure the proteome?FAQ on the Nautilus Resources pageBlog post – Genomics vs. proteomics: Two complementary perspectives on lifeWhat can and can't you do with proteomics?Translating Proteomics episode – Plasma Proteomics: The Dream and the NightmareLearn how the Nautilus Platform is designed to enable comprehensive broadscale proteomics and targeted proteoform studiesWhat are key proteomics methods and techniques?Blog series – Traditional protein analysis methodsBlog series – Next-generation proteomics technologiesWhat are the major pitfalls when doing proteomics?What are the challenges in proteomic data analysis?Translating Proteomics episode – Biology in Space and TimeBlog post – What is multiomics?What are people excited about in proteomics?Translating Proteomics episode – Poised for a Proteomics BreakthroughTranslating Proteomics episode - US HUPO 2025 – Key Takeaways, Trends, and Future Directions for ProteomicsTranslating Proteomics episode –

EAU Podcasts
Assoc. Prof. J. Gomez Rivas and Dr. E. Castro explore the importance of genomics and biomarkers in localised PCa

EAU Podcasts

Play Episode Listen Later Apr 12, 2025 19:20


In "Episode 1" of the series "Present and future of diagnostics in prostate cancer," Assoc. Prof. Juan Gomez Rivas (ES) and Dr. Elena Castro (ES) explore the importance of genomics and biomarkers in localised prostate cancer.The episode reviews why these diagnostic tools are pivotal in the changing landscape of prostate cancer, offering a deeper understanding of their current and future role in patient care.Assoc. Prof. Gomez Rivas and Dr. Castro discuss how these advancements in molecular profiling and biomarker testing can revolutionise the diagnosis and management of prostate cancer. Their conversation highlights the evolving nature of prostate cancer diagnosis, offering valuable perspectives on how genomics and biomarkers are shaping the future of personalised treatment strategies.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

This Week in Health IT
Keynote: Upcoming Healthcare Challenges and the Innovations to Solve Them with Justin Brueck

This Week in Health IT

Play Episode Listen Later Apr 10, 2025 36:07 Transcription Available


April 10, 2025: Justin Brueck, System VP of Innovation and Research at Endeavor Health, explores the balance of today's operational challenges with tomorrow's transformational needs. Justin discusses how healthcare systems are caught in a dichotomy—constantly putting out fires while trying to build a "fireproof house" through strategic innovation. How will healthcare address the looming workforce crisis as the "silver tsunami" approaches, with 42% of physicians between 55-65 years old? The conversation weaves through personalized medicine via genomics, the role of AI beyond the hype, and the critical importance of building trust when implementing new technologies. Key Points:03:55 Current Landscape of Healthcare Innovation07:22 The Role of Genomics in Healthcare17:34 AI and Its Impact on Healthcare27:40 Leading Organizational Change and InnovationX: This Week HealthLinkedIn: This Week HealthDonate: Alex's Lemonade Stand: Foundation for Childhood Cancer

TechSurge: The Deep Tech Podcast
Inside Microsoft's Trillion Dollar Playbook with Chief Strategy Officer Bobby Yerramilli-Rao

TechSurge: The Deep Tech Podcast

Play Episode Listen Later Apr 10, 2025 47:32


Bobby Yerramilli-Rao, Chief Strategy Officer at Microsoft, joins TechSurge host Sriram Viswanathan to offer a rare glimpse into the strategic playbook of one of the world's most powerful tech companies. Bobby shares how the company navigates today's biggest technology paradigm shifts, placing bets with trillion-dollar implications. Touching on Microsoft's AI strategy, OpenAI partnership, quantum computing, its approach to acquisitions, and much more, this candid and wide-ranging conversation is not to be missed. If you enjoy this episode, please subscribe and leave us a review on your favorite podcast platform. Sign up for our newsletter at techsurgepodcast.com for exclusive insights and updates on upcoming TechSurge Live Summits.

Food Safety Matters
Ep. 191. Dr. Edward Dudley: Wastewater Monitoring for Foodborne Pathogen Surveillance

Food Safety Matters

Play Episode Listen Later Apr 8, 2025 72:04


Edward G. Dudley, Ph.D. is the Director of the E. coli Reference Center and a Professor of Food Science at the Pennsylvania State University. He has a broad background in molecular biology, physiology, and foodborne bacteria genomics, with expertise in both beneficial and pathogenic species. His current research program focuses on factors that drive the virulence of Escherichia coli O157:H7 and the development of DNA sequence-based methods for tracking pathogen spread during foodborne illness outbreaks, including wastewater monitoring. Dr. Dudley is a past Chair of the Food Microbiology Division of the American Society of Microbiology (ASM), the Food Microbiology Representative to ASM's Council of Microbial Sciences, and a previous member of ASM's Microbe Program Committee. In 2019, he was appointed an ASM Distinguished Lecturer and Co-Editor of the Evolution and Genomics domain for ASM's online journal, EcoSal Plus. He was also elected to the American Academy of Microbiology in 2023. Dr. Dudley holds a Ph.D. in Bacteriology and an M.S. degree in Food Science, both from the University of Wisconsin–Madison. In this episode of Food Safety Matters, we speak with Dr. Dudley [35:17] about: A study conducted by Dr. Dudley's lab that investigated the usefulness of wastewater monitoring for surveillance of foodborne Salmonella illnesses How whole genome sequencing (WGS) was used to link Salmonella isolates from wastewater systems in central Pennsylvania to an existing salmonellosis outbreak The significance of discovering the rare S. Baildon serotype in the wastewater samples How wastewater monitoring activities could fill gaps created when foodborne illnesses go underreported by infected people, as well as the potential limitations of wastewater monitoring for foodborne illness surveillance Other foodborne pathogens besides Salmonella that could be surveilled via wastewater monitoring Apart from the Salmonella wastewater monitoring study, various research projects carried out by Dr. Dudley's lab related to E. coli. Before we speak to Dr. Dudley, we also hear from Patrick Schneider [25:37], Vice President of Operations and Engineering (Chlorine Dioxide) at CDG Environmental LLC. In his interview, he discusses the usefulness of chlorine dioxide for food plant sanitation, and what makes CDG Solution 3000TM the “gold standard in chlorine dioxide solutions.” Prior to joining CDG Environmental, Mr. Schneider spent 35 years holding various global roles in the oil and gas industry. He holds a B.S. degree in Petroleum Engineering from Penn State University. News and Resources News FDA Delays FSMA 204 Traceability Rule Compliance Date by 30 Months [4:02]FDA Launches ‘Operation Stork Speed' to Improve Infant Formula Safety, Including Contaminant Testing [11:08]Thousands More Layoffs Coming to FDA, CDC as HHS Announces Major Restructuring [12:06]Microplastics Increase Antibiotic Resistance of E. coli, Aid Biofilm Formation, Study Shows [18:12]Proposed Rule Would Require Mandatory Labeling on Alcoholic Beverages for Big 9 Food Allergens [22:35]Trump Admin Nominates CDC Acting Director Dr. Susan Monarez as Agency's Next Director [23:10]Boar's Head Appoints Natalie Dyenson as Chief Food Safety Officer [24:09] Resources Get 20 percent off your 2025 Food Safety Summit registration with code “FSMatters20” Wastewater Monitoring Can Aid Foodborne Illness Surveillance, Study Shows Wastewater Surveillance Useful for Norovirus Outbreak Detection Presenting Sponsor: CDG Environmental Visit CDG Environmental at Booth #333 at the 2025 Food Safety Summit! We Want to Hear from You! Please send us your questions and suggestions to podcast@food-safety.com

FYI - For Your Innovation
Breaking The $100 Genome Barrier: How Ultima Genomics Is Revolutionizing DNA Sequencing With Gilad Almogy

FYI - For Your Innovation

Play Episode Listen Later Apr 3, 2025 57:45


DNA sequencing is on the cusp of a major transformation, and Gilad Almogy, CEO of Ultima Genomics, is leading the charge. In this episode of FYI, ARK's Chief Futurist, Brett Winton, and Multiomics analyst Nemo Despot explore how Ultima is making whole-genome sequencing radically cheaper—driving costs down from $1,000 to just $80 per genome, with ambitions for even further reductions. Gilad shares how his background in semiconductors shaped Ultima's innovative approach, which relies on cost-efficient silicon wafers and high-throughput sequencing. The conversation also dives into the massive potential applications for low-cost sequencing, from cancer diagnostics and population genomics to AI-driven drug discovery.Key Points From This Episode:How Ultima Genomics' unique approach is slashing sequencing costsThe growing role of AI in understanding biologyWhy sequencing demand is highly elastic—cheaper data unlocks new applicationsThe future of personalized medicine and real-time cancer detectionHow population-scale genomics will transform healthcare

Artificial Intelligence in Industry with Daniel Faggella
Breaking Down AI's Role in Genomics and Polygenic Risk Prediction - with Dan Elton of the National Human Genome Research Institute

Artificial Intelligence in Industry with Daniel Faggella

Play Episode Listen Later Apr 1, 2025 20:03


Today's guest is Dan Elton, a Staff Scientist at the National Human Genome Research Institute (NHGRI) at the National Institutes of Health (NIH). Dan returns to the program to explore how AI is advancing genetic research, from protein engineering to gene editing and risk prediction. One of the most significant breakthroughs in this space is AlphaFold, DeepMind's AI model that predicts protein structures with unprecedented accuracy. While it does not analyze genetic sequences directly, its ability to model protein folding is transforming drug development and protein engineering. Dan also discusses the potential for AI to improve polygenic risk prediction, where machine learning models are being applied to assess disease risk based on genetic markers. If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!

Life Science Success
Inside the Gene Code: Bioinformatics Revealed with Dr. Edwards

Life Science Success

Play Episode Listen Later Mar 28, 2025 52:14


Send us a textIn this episode of the Life Science Success Podcast my guest is Michael Edwards, the founder and CEO of Bioinfo Solutions LLC, a data analytics company specializing in extracting insights from complex biological information. Dr. Edwards brings over two decades of experience in genomics, spanning from laboratory research to teaching data science and bioinformatics, with a passion for deciphering the genetic language of cells.00:00 Introduction to Life Science Success Podcast00:38 Sponsor Message: Bio on the Bayou 202502:12 Guest Introduction: Michael Edwards02:36 Michael's Journey into Genomics and Bioinformatics05:07 Key Milestones in Michael's Career08:18 Founding Bioinfo Solutions09:31 Diverse Projects and Client Engagements15:38 The Role of Bioinformatics in Modern Research22:28 Challenges and Insights in Data Analysis27:00 Exploring Methodologies and Exciting Projects28:05 Gene Expression as a Language30:22 Future of AI in Bioinformatics31:17 Networking and Data Visualization32:20 AI and Automation in Various Fields38:12 Importance of Statistics and Data Visualization41:09 Broadening Skills and Tools in Bioinformatics44:07 Inspiration and Concerns in Science48:52 Concluding Thoughts and Reflections

DNA Dialogues: Conversations in Genetic Counseling Research
#14- Cardio & Genetics: Exploring Revenue & Best Practices

DNA Dialogues: Conversations in Genetic Counseling Research

Play Episode Listen Later Mar 27, 2025 56:32


In this episode, we are discussing 2 articles focused on cardiovascular genetics. In the first segment, Khalida talks to authors Marianne and Erin about their research exploring the opportunities for downstream revenue of cardiac genetic counseling services in a pediatric medical center. In the second segment, Naomi chats with Jodie and Erin about the recent NSGC Practice Resource about genetic testing and counseling for hypertrophic cardiomyopathy. Segment 1: Cardiac genetic counseling services: Exploring downstream revenue in a pediatric medical center Marianne Olson, MS, CGC is a genetic counselor at Baptist Health in Kentucky. She provides prenatal genetic counseling at Maternal Fetal Medicine clinics in Louisville and Lexington. Marianne graduated from the Cincinnati Genetic Counseling Graduate Program in 2024. Prior to working as a genetic counselor, Marianne taught high school chemistry and biology for 12 years. Erin Miller is an Associate Professor in the University of Cincinnati College of Medicine. Erin is a genetic counselor IN THE DIVISION OF CARDIOLOGY at Cincinnati Children's Hospital Medical Center. She leads the cardiology genetic counseling team in providing genetic counseling services to individuals of all ages with and at risk for cardiovascular disease. Erin is focused on improving access to genetics services for families with inherited cardiovascular diseases. In this segment we discuss: - What sparked the decision to explore downstream revenue (DSR) in a cardiac genetic counseling setting - Financial challenges institutions face when hiring genetic counselors, especially around reimbursement - The role of genetic counseling in reducing costs by guiding risk stratification and avoiding unnecessary testing - Limited uptake of cardiac screening among at-risk relative and strategies that could help improve adherence - How findings from this study can support the case for sustaining genetic counseling roles within pediatric cardiology - Potential to adapt the study's methodology to other specialties like neurology or prenatal genetics, and considerations for doing so   Segment 2: Genetic testing and counseling for hypertrophic cardiomyopathy: An evidence-based practice resource of the National Society of Genetic Counselors Erin Miller (she/her) is an Associate Professor in the College of Medicine at the University of Cincinnati and a cardiac genetic counselor at Cincinnati Children's Hospital Medical Center in the Division of Cardiology. She leads the cardiology genetic counseling team in providing genetic counseling services to individuals of all ages with and at risk for cardiovascular disease. Erin is focused on improving access to genetics services for families with inherited cardiovascular diseases. Associate Professor Jodie Ingles (she/her)  is Head of the Clinical Genomics Laboratory and Program Director of Genomics and Inherited Disease Program at Garvan Institute of Medical Research. She is a cardiac genetic counsellor in the Department of Cardiology, Royal Prince Alfred Hospital Sydney. Her team is focused on using genomics to improve diagnosis and care of families with inherited cardiovascular diseases. In this segment we discuss: - The motivation behind creating an official practice resource focused on genetic testing and counseling for HCM - Deep dive into the first major recommendation: offering genetic testing to all individuals with a suspected or confirmed diagnosis of HCM, paired with appropriate genetic counseling - Exploration of the second recommendation: ensuring that genetic tests are selected, ordered, and interpreted within the context of genetic counseling, and the complexities that come with this process - Discussion of the third recommendation: providing cardiac and cascade genetic testing to at-risk relatives, without age limitations, and why this is critical for effective family-based care - A look at the barriers to integrating genetic services into cardiology practices, especially in settings without dedicated genetics expertise   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors. Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.  For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.  Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.  DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Sydney Arlen.  

Heredity Podcast
Golden bandicoot and Australian conservation genomics

Heredity Podcast

Play Episode Listen Later Mar 26, 2025 22:41


Best student paper of 2024 winner Kate Rick, along with Brenton Von Takach and Kym Ottewell, discuss the use of genomics in Australian conservation efforts, and their study on the golden bandicoot. Hosted on Acast. See acast.com/privacy for more information.

Intelligent Medicine
Vitamin D: How Rickets Shaped Nutritional Science, Part 1

Intelligent Medicine

Play Episode Listen Later Mar 25, 2025 28:15


The Long Shadow of Rickets: Vitamin D, Historical Insights, and Modern Implications. Dr. Chris Warren, a history professor at Brooklyn College delves into the origins and prevalence of rickets, a condition now largely unknown but once widespread. Dr. Warren explains the factors contributing to rickets, particularly Vitamin D deficiency, and shares insights from his book, "Starved for Light: The Long Shadow of Rickets and Vitamin D Deficiency." The discussion covers socioeconomic, industrial, and environmental aspects, along with the relevance of cod liver oil, sunlight exposure, and the evolution of Vitamin D synthesis. There are also reflections on modern implications of Vitamin D deficiency and racial differences in processing Vitamin D. The episode concludes with a look at how historical medical practices around rickets influenced today's medical norms and practices.

Raise the Line
Helping All Medical Providers Understand Genomic Testing: Dr. Ethylin Wang Jabs, Mayo Clinic and Dr. Antonie Kline, Harvey Institute for Human Genetics

Raise the Line

Play Episode Listen Later Mar 20, 2025 16:06


An interesting new study from the Geisinger health system in Pennsylvania examining if genomic screening in a large population increases the identification of disease risk prompted Raise the Line to re-release a previous episode about a textbook designed to help all medical providers understand the clinical applications of genomic testing. Genomics in the Clinic: A Practical Guide to Genetic Testing, Evaluation, and Counseling from Elsevier Science Direct dives into the use of this important tool in diagnosis and screening, indicating how individuals may respond to drug therapies, and more. “We really need to educate all healthcare providers about the practice of genetics because they're going to be involved directly or indirectly in genetic testing and conveying information about what the results mean to patients and their families,” explains co-author Dr. Ethylin Wang Jabs, enterprise chair of the Department of Clinical Genomics for Mayo Clinic. Jabs and her co-author, Dr. Antonie Kline, director of Clinical Genetics at the Harvey Institute for Human Genetics at Greater Baltimore Medical Center, chose a format that makes heavy use of case studies to help readers get a better grasp on this complicated field and they also include chapters on direct-to-consumer testing and the ethical and social implications in genomic medicine. “Any kind of potentially predictive testing can have ethical issues related to it, including insurance coverage, testing for family members, protections for minors, and more,” says Dr. Kline. Join host Caleb Furnas for an illuminating episode on an area of discussion in medicine that's growing in importance as the use of genetic testing rapidly increases. Mentioned in this episode: Genomics in the Clinic: A Practical Guide If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/raisethelinepodcast

The G Word
Vivienne Parry, Alice Tuff-Lacey, Dalia Kasperaviciute and Kerry Leeson Bevers: What can we learn from the Generation Study?

The G Word

Play Episode Listen Later Mar 19, 2025 34:03


As of February 2025, the Generation Study has recruited over 3,000 participants. In this episode of Behind the Genes, we explore what we have learnt so far from running the study and how it continues to evolve in response to emerging challenges. The conversation delves into key lessons from early recruitment, the challenges of ensuring diverse representation, and the ethical considerations surrounding the storage of genomic data. Our guests discuss how ongoing dialogue with communities is helping to refine recruitment strategies, improve equity in access, and enhance the diversity of genomic data.  Our host Vivienne Parry, Head of Public Engagement at Genomics England, is joined by Alice Tuff-Lacey, Program Director for the Generation Study; Dalia Kasperaviciute, Scientific Director for Human Genomics at Genomics England; and Kerry Leeson Bevers, CEO of Alström Syndrome UK. For more information on the study, visit the Generation Study website, or see below for some of our top blogs and podcasts on the topic: Podcast: What do parents want to know about the Generation Study? Podcast: How has design research shaped the Generation Study? Blog: What is the Generation Study? "We always have to remember, don't we, that if people say no to these things, it's not a failure to on our part, or a failure on their part. It's just something they've thought about and they don't want to do, and for all sorts of different reasons. And the other reflection I have about different communities is the ‘different' bit, is that what approach works for one community may not work for another, and I think that that's something that's going to have to evolve over length of the study, is finding the things that are the right way, the most helpful way to approach people." You can download the transcript, or read it below.   Vivienne: Hello and welcome to Behind the Genes.    Alice: “And this is quite an exciting shift in how we use whole genome sequencing, because what we are talking about is using it in a much more preventative way. Traditionally, where we've been using it is diagnostically where we know someone is sick and they've got symptoms of a rare condition, and we're looking to see what they might have. What we're actually talking about is screening babies from birth using their genome, to see if they are at risk of a particular condition, and what this means is this raising quite a lot of complex ethical, operational, and scientific and clinical questions.”    Vivienne: My name's Vivienne Parry, and I'm Head of Public Engagement here at Genomics England, and I'm your host on this episode of Behind the Genes.      Now, if you are a fan of this podcast, and of course you're a fan of this podcast, you may have already heard us talking about the Generation Study, the very exciting Genomics England research project which aims to screen 100,000 newborn babies for over 200 genetic conditions using whole genome sequencing.      Well, we've got more on the study for you now. What we're doing to make it both accessible and equitable for all parents-to-be, and our plans to ensure that we continue to listen to parents, and perhaps in future, the babies as they grow up. We'll chat, too, about emerging challenges and how we might deal with them.    I'm joined in our studio by Alice Tuff-Lacey, the Programme Director for the Generation Study, and Dalia Kasperaviciute, Scientific Director for Human Genomics, both from Genomics England, and we're delighted to welcome Kerry Leeson-Bevers, Chief Executive of Alström Syndrome UK. And I'm just going to quickly ask Kerry, just tell us about Alström Syndrome and how you're involved.    Kerry: Yes, so Alström Syndrome is an ultra-rare genetic condition. My son has the condition and that's how I got involved. So, the charity has been around now since 1998, so quite a well-established charity, but as part of our work we developed Breaking Down Barriers, which is a network of organisations working to improving engagement and involvement from diverse, marginalised and under-served communities as well.    Vivienne: And you wear another hat as well?  Kerry: I do. So, I'm also a member of the research team working on the process and impact evaluation for the Generation Study. So, I'm Chair of the Patient and Public Involvement and Engagement Advisory Group there.    Vivienne: Well, the multiply hatted Kerry, we're delighted to welcome you. Thank you so much for being with us.      So, first of all, let's just have a sense from Alice Tuff-Lacey about this project. In a nutshell, what's it all about, Alice?  Alice: Thanks Viv. So, I think in the last few years we've seen some really big advances in the diagnoses of rare diseases through things the Genomic Medicine Service. But we know it takes about 5 years often to diagnose most of these rare conditions. What we also know is that there are several hundred of them that are treatable, and actually there can be massive benefits to the child's health from diagnosing and treating them earlier. I think a really good example of this which is often talked about is spinal muscular atrophy, which is a particular condition where there is a genetic treatment available and there is a really big difference in families from those babies where the condition was identified later on, versus their brothers and sisters where they were identified early because they knew there was a sibling that had it and they were given that treatment.     What we think there is a huge potential opportunity to identify these children from their genome before they get ill, and this is quite an exciting shift in how we use whole genome sequencing, because what we are talking about is using it in a much more preventative way.  But this is a really different approach to how we've been using it so far, because traditionally where we have been using it is diagnostically where we know someone is sick and they've got symptoms of a rare condition and we are looking to see what they might have, what we are actually talking about is screening babies from birth using their genome to see if they are at risk of a particular condition. And what this means is, this raises quite a lot of complex ethical, operational and scientific and clinical questions.      So the aim of the Generation Study is really to understand if we can and should use whole genome sequencing in this way to screen for rare conditions in newborn babies. We've been funded by the Department of Health and Social Care to do this over the following years, and the way we'll be doing this is by a national study across a network of trusts in England where we are aiming to recruit about 100,000 babies and screen them for rare treatable conditions that we know present in childhood. And really the aim of this is to understand if this will work and how it will work, and to generate the evidence to allow the NHS and the National Screening Committee to decide if this could become a clinical service, and that's very much the primary goal of the study.      Beyond that, however, there are some other aims of the study, and we also consent mothers to ask permission to retain their genomic data and to link it to the baby's clinical data over their childhood, and we'll be providing access to this to researchers in the de-identified way in our trusted research environment. And this is to really understand if that data can also be used to further generate information around other discovery research, but also critically understand that the motivations for parents involved will be very different, and we need to think very carefully about how we engage and work with the parents of the babies going forward about how we use their data.    Vivienne: And the super exciting thing is we've started recruiting. How many mothers have we recruited?  Alice: So, we've recruited over 3,000 to date, and it's building every day and every week really. And it's really exciting because we see more and more trusts coming online and the study building and really starting to learn from the experience. And every week and every month, we're learning much more about how this process works, what the impact it's having, and kind of what we need to do over the coming few months and years to deliver it.    Vivienne: And we did a huge about of work at Genomics England before the study even started, to try and find out what people wanted. So, we found out, for instance, that people didn't want to know about late onset conditions, they did want to know about conditions where there was a treatment, and they wanted things that could be done for their babies in childhood. So, we had a really clear steer from the public about this project before we even started. So, how are we continuing to learn from the people who are involved in the study and the public? I mean Kerry, you've been involved in this aspect. We need to listen, don't we, to find out what's going on?    Kerry: We do, we do, and I think it's really encouraging to see the public dialogue and the amount of engagement work that was done there to kind of identify what some of those areas were, but it's really important that we don't stop that engagement there. It's really important to continue that, and I know that we've got quite a diverse group for our Patient and Public Involvement Advisory Group and the Evaluation Team, and one of the things they're really interested in is how we're going out there to speak with communities. You know, we can't just be reliant on the media, and press releases about the study. We need to actually go to communities and have these conversations so that people can have a conversation within an environment that they feel safe and confident with the people that they feel supported by as well.    So I think it's really key that we continue to ask those questions but also learning from the evaluation and, as we go through the process, of speaking to the patient organisations as well who support families that suffer from some conditions that we plan to identify through this study, and learn what some of their challenges are as well. You know, do they feel equipped to be able to support parents that are getting a diagnosis? As well as obviously their participants and the general public, to make sure that we're aware of attitudes and perceptions as the study goes along.    Vivienne: Because there's always a danger with this kind of study that it's people who are health literate who end up being involved. Whereas some of the people on whom the burden of rare disease is greatest may not either feel that they can access, or would want to access, this study. So, what are we doing there? How are we listening to people?  Kerry: When we are looking at recruitment as well, like you say, you know this is a research study and when we look at history and when we look at participants in research studies, we very rarely do you get a diverse representation of people in these types of studies. So, it's really important that those extra efforts are made really in terms of recruitment to get the right sample of people involved. And I know at Genomics England, that they have invested their time and money in terms of interpreters and translating materials and things, but actually it's the sites and recruiting people that need to be well resourced in order to use recruitment strategies, because if we're just looking at posters in waiting rooms, for instance, you're going to get a particular demographic of people that will respond to those kind of posters, such as people who don't speak English as a first language, it would be really difficult sometimes to read those kinds of posters and then to ask questions about that.     We need skilled people within sites that are recruiting who have got cultural competence who can have those conversations, address some of those areas, some of those concerns so that we can get that diverse representation.    Vivienne: So, there's a whole piece about equity of access for everybody and Dalia, perhaps you can explain why this is so important, scientifically as well as ethically? There's another piece about making sure that we get a full diversity represented.    Dalia: We know that some of the conditions are more common in certain populations or certain communities. We also know that some of the conditions are caused by certain variants in one population but not in the others. And these genetic causes even of the same condition can vary between different communities and different genetic ancestors.  On the other hand, our knowledge about the conditions and the genes, and the variants which cause them, come a lot from what we've seen before. Where we've seen those variants in the patients with the disease, and importantly where we've seen those variants in control populations where these individuals which don't have conditions.      Therefore, if we lack the diversity in our datasets, we would not know about all the diverse reasons of why conditions can be caused, or how it progresses, or what it might mean for individuals. And we would not be able to have equitable testing, or we wouldn't know whether the test works for everyone. If that happened, we might be in the territory where we can't detect or don't detect as well all the conditions across different individuals. But also, we may be having more false positive results and create more anxiety for families as well as burden for healthcare system.    Vivienne: So, are you saying, Dalia, that actually sometimes we might get a false positive, or indeed a false negative, simply because in that person, the condition which we think is usually caused by a particular change, they've got a slightly different change and so therefore we're not picking it up.  Dalia: Indeed, but it's one of the possibilities. If, let's say, all our knowledge about certain genes came from a limited number of individuals, seeing a new variant in another individual might seem that it's something really rare and never seen before and it's potentially changes how the gene functions, we would say; “oh that's maybe something which causes the disease,” when actually it can be that it is a benign variant, just a normal variation which is very common in another part of the world, it's just that we don't have enough data to know about it. So, we need to be aware of those risks and take it into account when we interpret the variants.      And, we also need to be transparent when operating in the environment. There was historical and investment in the diversity in research and our data sets still are not as diverse as we would like to be. It's shifting, the balance is definitely shifting in the last few years. A lot of effort is being done but the only way to shift the balance forever and make that genomic medicine work for everyone is to really actively engage those individuals and involve them in the research, and taking all the effort that Kerry was talking about.    Advert: The Genomics England Research Summit is fast approaching and registration is now open! Join us for this one day in-person event on Tuesday 17 June 2025. This year's agenda dives into rare condition diagnosis, cancer genomics, pharmacogenomics, therapeutic trials, and the impact of emerging technologies. Hear from leading experts and inspirational speakers as we explore the present and future of genomics and the latest research and technology from the Genomics England research community. Keep an eye on the website, genomicsresearchsummit.co.uk for all the details and to secure your spot. Spaces are limited, so don't miss out. We'll see you at the summit!  Vivienne: Alice, that goes back to this thing about holding the genomic data, because you need to hold the genomic data because the thing about genomics as always, you need to know what happens next. So, for instance, if somebody had a negative result and then later developed a condition, you need to be able to go back that data in order to find out what the problem was.  Kerry: That's right. You know, as Dalia talked about, we know that there is a risk within the study and we try and be clear about that in our participant information that there are some babies where they may have a genetic condition that we will need not find it, and others where we might find something that doesn't go on to be the actual condition. And we need to kind of monitor those in different ways.      So in particular in the cases where, if we've returned a result where we don't think we suspect a condition and a baby goes on to develop a condition, it's quite complex how we monitor that, and we're trying to go for a multi-track approach, and I think a lot of the benefits is some of the infrastructure that Genomic England already has that we can utilise.  So, some of the foundational things we've put into the study to help support the approach are things like the ability to contact parents regularly so we can actually work with them to find out over time if their babies develop conditions.    As you say, ability and consent to access the clinical data about the baby so that we can then access national data sets, and then we can then potentially monitor to see if babies seem to be showing signs of developing a condition. And also, really continuing to work with a network of clinical specialists where we've work quite hard over the last couple of years to build that kind of network and engage with them about the study, because they'll be the ones who the babies will come to if they develop those conditions. So, they are a really good route to us finding out, whether or not there are babies who have been part of the study who then go on to develop a condition.     And I think the reality is that this is a really complex process and it's something that even traditional screening programmes really struggle with, and that's why this multi-pronged approach is really important, and why also we see that this approach will evolve over time, and at the moment, the important thing is we've worked hard to put the right foundations in to allow us to do this type of monitoring, and to really evolve that approach as things develop and as more things come along potentially where we can invest in.    Vivienne: So, it's interesting, isn't it, because I guess that some parents would think that if you get a false positive or false negative, that it means that the test is at fault. And actually the accuracy of the test is good, but what we may have an issue with is that there is something else causing the problem that we don't yet know about. So, a big part of this project is giving much, much more information about the causes of conditions.    Alice: Yes, and I think that's also why the discovery research aspect is really important, the fact that we consent for that ability to hold the baby's data. So not only will we want to use it for the evaluation, but as I mentioned at the beginning, we have asked for parents to be able to allow us to link it to clinical data which then allows us to track over time and find out more information, because it's always the quality of the information we know that will help us in the future to identify these conditions, so the more we can generate potential information, you know, the more we will learn as a society.    And so it's actually quite an altruistic thing we're asking of parents, and that's something we recognise and that's why it's also important we think about, how we continue to engage with the parents and the baby over their lifetime to remind them that we're holding this data, but also to understand what their concerns and feelings are about us holding that data and how we're using it for that broader research.  Vivienne: And that's very much what you're involved in, isn't it Kerry?  Kerry: Yes, and I think sometimes in some ways that may offer some reassurance to parents as well, to know that's there as a reference point if things do develop over time, but I know that one of the things we're looking at as part of the evaluation, and the PPI Group we're involved in, is looking at the experiences of patients through this journey because actually it will create quite a lot of uncertainty.      As a parent of a child with a genetic condition, that uncertainty really is one of the hardest things to learn to live with. So at that early stage, one of the things we're looking at is that experience, how much support people have received, whether that has an impact on the parent and their child and their on bonding and their experiences and things like that, and I think it is important that we do that, but I think also having those references, where you're able to go back and ask those questions, that's really important that the support is in place, and that pathway really for parents to know where to go to. Because sometimes, although we may arrange to have calls at regular intervals and things, sometimes the questions of parents don't necessarily come at the time when they are having a telephone call. They come really late at night when there's nobody to pick up the phone, so having as much information as we can available, and those support structures in place, is really key.    Vivienne: We all start off these projects thinking that they are going to go in a particular way, but actually there's a lot of flexibility in this study, isn't there, Alice?  For instance, we will be looking at all those false positives, false negatives because we need to learn from that. We will be, perhaps, changing our approach as we go on if there is something that isn't working out. Is that what we're doing?  Alice: Yes, I think what we have recognise is it is a study and therefore that involves learning by it's very nature, and that's why partly we're working with external evaluation partners that Kerry's involved with, but also why we invest in a lot of things internally. Like we do a lot of user research with our midwives and our participants, and also potential participants. Because, actually we don't know the answer to this. No one's done this before, and so this is about all of us really learning, and learning in the right way and continuing to do that throughout the study, but also more importantly capturing that information and making sure that at the end of it, we then have some understanding of if we were to see that it's right to deliver this as a clinical service, what that might actually involve.      But also, even if we get to that point, I think beyond that we will still continue to learn over time and that's again why that long enduring consent is quite important, because we can then continue to maintain that long term evaluation and continue to maintain that long term potential to help further further research. And so that's the thing where actually we'll be learning for the next 10-15 years, really what the Generational Study has learnt, and actually what we have achieved through it.  Vivienne: I just want to move back to something that you mentioned, Kerry, about conditions that we're looking for, and there were a lot of very specific things. I've said that what parents wanted, but there's also some scientific things, and Dalia might want to come in here, that these are conditions that we pretty sure that if you've got the particular genetic change, that you will get the condition – something called penetrance. So, you know, we're not leaving people with a lot of uncertainty. But, how will we go about assessing new conditions as part of this study, or are we just on the ones that we're on at the moment?  Dalia: So, we started from the things we understand the best and we know how to detect them and we know how to confirm them because the tests that we are doing in Genomics England is a screening test, it will not be a definitive answer whether you have or you don't have a condition. Anyone which will get a positive result will be referred to an NHS specialist clinician for further assessment. And some of those positive results turn out not to have the conditions and some of them will have, and they will have their treatment pathways. So, we're started to very cautiously, and that's what came from public dialogue, everyone was saying that; “you need to be really cautious, we need to see that it works for the conditions that we understand well”.     But as a starting point, as we learn more, we're learning of how could we expand that list.  What would be acceptable for public. Maybe some conditions will have an experimental treatment, which currently would not be included in screening but as treatments evolve, at some stages maybe there will be opportunities to include some conditions in the future.      As our science evolves, we keep assessing the new conditions and seeing can we include them, would it be acceptable to parents, would it be acceptable to the healthcare system, and one of the things about screening it's really important not to cause harm. There are a lot of benefits in screening but if we didn't do it cautiously, it also has some risks, and we need to be very careful about it.    Vivienne: Now Kerry, there are lots of parent groups who will come along to us and say; “oh you must include this condition,” but perhaps there isn't yet a treatment, or there isn't a pathway in the NHS that will help people get what they need. And I guess if we try to include too many conditions, we would actually undermine trust.    Kerry: So, the patient organisation, our condition, Alström Syndrome, isn't included in the list. For our condition, there is no specific treatment although we do have a highly specialised service, and it is very important to get early diagnosis because children can develop heart failure and there are symptom-specific treatments available there. But I get the reasoning why there needs to be a specific treatment and the need to include just a smaller group at the beginning, but our hope as with I'm sure a lot of other patient organisations, is that our condition will be added at a later time if it is found that this is something that would be acceptable in routine care.    Advert: If you're enjoying what you've heard today and you'd like to hear some more great tales from the genomics coalface, why don't you join us on the Road to Genome podcast, where our host, Helen Bethell, chats to the professionals, experts and patients involved in genomics today. In our new series, Helen talks to a fantastic array of guests including the rapping consultant, clinical geneticist Professor Julian Barwell about Fragile X Syndrome, cancer genomics and the holistic approach to his practice. A genuine mic-drop of an interview. The Road to Genome is available wherever you get your podcasts.  Vivienne: Let me move on to another aspect of this study. These are babies, and we are holding their genomic information but at 16, they will be able to decide whether they want us to continue holding their genomic information. Alice, is that very much part of this programme to think about what we're going to say and how we're going to engage those 16-year-olds?  Alice: Yes, it very much is. What I always say, because I get asked this question a lot, is that I don't think we can pre-judge what that looks like. Because I look at my children, and certainly their lives are very different from my childhood, and I don't think we can imagine exactly what our babies will look in 16 years and what that world looks like. I think the important thing is many of things we are trying to do is that we lay the right foundations in place, and part of that is ensuring that we continue to think about how we engage with young people as the study evolves and over time, so that we understand what the world is looking like from their perspective.      But also, how do we equip the parents to talk about the fact that these babies are part of the study to them? What does that look like? How can we support them? And that's very much something we want to be looking at in the next year, really working with parents from the Generation Study to understand how best we can do that so that they can have some of that conversation for themselves as well. I think we can't pre-judge exactly how we need to talk about them and also not think it's just one thing. We need to evolve and work with the children as they grow up, and work with their parents to equip them because, as I said, we don't really know how they're going to access information in the future. You know certainly TikTok didn't exist when I was a child, and so that's what we've got to think about is what's the best avenues or forums to really engage properly with them as they grow.  Vivienne: Kerry, what other concerns to parents have that we're learning now?    Kerry: I think the concern is that when treatments are being developed, that they are not necessarily being developed for the whole population. They're often being developed for sub-sets of population because we don't have a complete dataset. And when you think about people being involved in research, people feel that they are being left behind because their data is not necessarily represented within there, it doesn't reflect their community, and it's not being discussed within communities, the different research opportunities and things have been available, I think it's the fact that we're not investing enough in community engagement and dialogue to explain more about genetics.   I think technology has advanced at pace. As a parent of a child with a genetic condition, that is very encouraging to see that, but I think sometimes the support and the information is not necessarily keeping up, so we're not having those open conversations really about genetics and genomics, and I think that's one of the things I hope that this study will really lead to, that it will now become much more part of everyday conversation.   Because often, when you have a child with a genetic condition, you first hear about a condition, the way you take in that information and ask questions is very different than having a conversation with the general public about genetics. When you're concerned that your child may have a condition or you may have a condition yourself, you're in a completely different mindset. So, the hope is that that dialogue will open so that people will be able to ask questions to learn more about the projects and things that are out there and available so that people are included and can take part in research if they want to. But it's important to remember that not everybody will want to. It's about being given informed choices and to do that we need to make sure that the support and the information is appropriate, inclusive and accessible.    Vivienne: We always have to remember, don't we, that if people say no to these things, it's not a failure to on our part, or a failure on their part. It's just something they've thought about and they don't want to do, and for all sorts of different reasons. And the other reflection I have about different communities is the ‘different' bit, is that what approach works for one community may not work for another, and I think that that's something that's going to have to evolve over length of the study, is finding the things that are the right way, the most helpful way to approach people.   Kerry: I completely agree. I think it's like you say, if people say no, that is completely their right to do so as long as they're saying no when they've been given the information to be able to really take that on board, think through, consider it and then make an informed decision. I think often people say no because they've not been given the right information to be able to understand what is expected, so they've not necessarily been given the opportunity. And I think we all want good outcomes for everybody. That doesn't mean delivering the services in the same way. Sometimes we need to deliver services in different ways because often services aren't very accessible for some communities to be able to access. So sometimes we need to make changes, adapt, to make sure that everybody has the same opportunities to the same outcomes.  Vivienne: We are constantly re-evaluating, rethinking, re-engaging to try and make it the best we can. Whether it's with different communities and different approaches. Whether it's with constantly assessing people who've had false positives, false negatives and finding out why that is the case. And in the future, I think this will have some really major effect.  Dalia, you're the scientist amongst us today. Tell us what you're hoping for from this study in science terms.  Dalia: So, first of all, we want to find the babies which we can treat before we develop symptoms, before we get ill, so that we can have more fulfilling lives. That's the bottom line. But we're doing that, we also will learn about the conditions. We'll learn a lot about the natural history of the conditions. What happens when you detect it before baby gets ill, then you start treatment, and how does it work in the diverse communities and diverse populations that we've talked about. Are there are any differences based on people's ancestry, but not just ancestry, about their lifestyle, about anything else which can affect how disease develops, or how the care or treatment goes.      So, that's kind of the bottom line. The top line and now our ultimate aim, probably many years from now, would be that we can detect variants of genes or conditions before they develop, and we can create treatments for them before our children get their conditions.  That's something that the science community is very excited about. I think we're quite a few years from that, but that's where we hope all this will be heading in the future.    Vivienne: It's really becoming a possibility, but the science is only the first part of it. It's the human interaction. It's the how it lands with people. It's how they feel about it. It's how they trust it. And these are all the things that we're really working on at Genomics England to make this study not just a scientific success, not just a success for the NHS, but also something that is really meaningful and important and valuable and trusted for people having babies. Would you agree?  Alice: Yes, 100%. I think, just to come in there, Viv, I think we've talked a bit about the importance of public trust and being the foundations of what we do, and I think that's something that Genomics England's always held true to itself, but I think for the purpose of the Generation Study, it's been one of kind of the foundational principles from the beginning, and I think Kerry and you have touched upon some really important themes today about how it's not a ‘one size fits all' approach. And I think very much that piece that we touched on a bit about, kind of, how do we make this accessible to everybody, we see it very much as not a ‘one size fits all', and so we've been trying lots of different things to really tackle that, and evolving the approaches which, as you said, that's where the flexibility comes in.      My hope for the next 12 months is that we can really, now that we've got the study up and running, work a lot with the some of the regional networks, the Genomic Medicine Service alliances who are working at the regional level, and the recruiting trusts, to really explore different approaches and work out how we can support them to engage with the communities in their areas, because they're the ones who will understand who they are, and our role is to really try and provide, as Kerry highlighted, the tools of support to allow them to do that, and to try and make sure that we can make this as equitable as possible in terms of people being able to at least understand the studies here, get the information in the appropriate way, and then as we have also talked about, making their own minds up about whether this is the right thing for them to be part of.    Vivienne: So, the final question for you all is if I'm a mother-to-be, where can I find out more information. Let's start with you, Kerry.  Kerry: Well, from the Generation Study website, there's information there. Midwives, GP practices, obviously they're often going to be your first port of call, so I'm hoping that they feel equipped to be able to answer those questions and to signpost people to one of the trusts that are involved.    Vivienne: And we've also got a Genomics 101 episode where we answer some of the frequently asked questions, and I think there are at least 2 or if not 3 separate episodes from Behind the Genes, which people can look for which look at different aspects of the project. Anything else, Alice, that we need to know?  Alice: So, Kerry highlighted it, the Generation Study website is a really good starting point, but that's a good place to also find out what trusts are involved because it's also important to know that this is not available in all trusts in England at the moment. We have a network and it's growing, and it is all around England, but the first place to start is, kind of, is it in your local trust?  And then from there, it's then engaging with your trust and hospitals where there will be information, and the midwives are prepared to kind of talk to people.  So those are, kind of, the good first places to start.    Vivienne: Well, we're going to wrap up there. It's been so good talking to you all. So, thank you to our guests Alice Tuff-Lacey, Kerry Leeson-Bevers, and Dalia Kasperaviciute for joining me as we talked through how the Generation Study is continuing to evolve as it responds to emerging challenges. Now, if you would like to hear more about this, then please subscribe to Behind the Genes on your favourite podcast app and, of course, we hope that you would like to rate this.  Because, if you rate it, it allows more people to see it and more people to get enthused about Behind the Genes, which we love. It's available through your normal podcast apps. I've been your host, Vivienne Parry. The podcast was edited by Bill Griffin at Ventoux Digital, and produced by Naimah Callachand at Genomics England. Thank you so much for listening. Bye for now.  

All CancerCare Connect Education Workshops
Breast Cancer in Men: Diagnosis, Treatment and Survivorship

All CancerCare Connect Education Workshops

Play Episode Listen Later Mar 19, 2025 50:53


- Overview of the Diagnosis & Treatment of Breast Cancer in Men - Detection of Breast Cancer in Men – Mammogram, Ultrasound, Biopsy - Grading & Staging of Breast Cancer - Understanding the Treatment of Breast Cancer in Men – Surgery, Radiation, Immunotherapy, Targeted Treatments - Definition of Genetics & Genomics of Breast Cancer in Men - Tools that Help Predict the Risk of Breast Cancer Recurrence in Men - How Genomic Testing Informs Breast Cancer Treatment Planning for Men with Breast Cancer - Critical Role of Genetic & Genomic Testing Throughout All Stages of Breast Cancer in Men - The Value of Early Testing to Inform Treatment Choices - Their Role in Selecting Your Best Cancer Treatment - The Role of the Pathologist - The Difference Between Inherited & Acquired or Sporadic Gene Mutations - Understanding the Types of Gene Mutations - Genetic Testing, Including Testing for BRCA Mutations - Preventing & Managing Treatment Side Effects & Long Term Effects of Breast Cancer Treatment in Men - Follow-Up Care - Survivorship Care Plan - Nutrition & Hydration Concerns & Tips - Support for Men Living With & Surviving Breast Cancer - Questions for Our Panel of Experts

HIMSSCast
HIMSSCast: The innovations and barriers of genomics

HIMSSCast

Play Episode Listen Later Mar 14, 2025 17:02


The cost versus the clinical insights

The Drug Discovery World Podcast
The revolutionary impact of understanding genomics

The Drug Discovery World Podcast

Play Episode Listen Later Mar 13, 2025 15:03


This is the latest episode of the free DDW narrated podcast, titled “The revolutionary impact of understanding genomics”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Open science, genomics, and the quiet revolution in our approach to pharma” and “Junk DNA: How the dark genome is changing RNA therapies”. In the first article, Evan Floden, CEO of Seqera Labs, examines how data sharing platforms are impacting cancer and genomics research. In the second article, Samir Ounzain, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics.

The Human Upgrade with Dave Asprey
Your Genes AREN'T Your Fate—The NEW Science of DNA Biohacking for SuperHuman Health | Sharon Hausman-Cohen : 1257

The Human Upgrade with Dave Asprey

Play Episode Listen Later Mar 6, 2025 78:33


For decades, we've been told that our DNA is a fixed blueprint—an unchangeable code that dictates our health and lifespan. But what if that's only half the story? Sharon Hausman-Cohen, a physician, researcher, and genomics expert at IntellxxDNA, joins Dave to reveal the cutting-edge science of genetic optimization—how understanding your DNA can unlock longer life, better brain function, and even protection from chronic disease. Forget the old-school genetic reports that left you with useless percentages. The new frontier of precision genomics goes beyond risk factors to actionable insights, showing you exactly how to turn on your body's most powerful longevity genes and turn off the pathways driving inflammation, cognitive decline, and disease. What You'll Learn in This Episode: • Why genetics alone don't determine your future—and how to use epigenetics to control your health • The truth about MTHFR, APOE4, and other “bad” genes—are they actually harming you? • How genetic reports can predict and eliminate brain fog, fatigue, and pain • The hidden genetic reasons behind ADHD, depression, and anxiety—and how to fix them • Why some people age faster—and the one longevity gene that determines your biological age • Cutting-edge breakthroughs in DNA-based biohacking—is it possible to edit your genes for peak performance? This is the future of personalized medicine. By understanding your own genetic blueprint, you can stop guessing and start making the precise changes that will optimize your energy, brainpower, and lifespan! ** Visit IntellxxDNA at https://intellxxdna.com/asprey/ When you go to the website to find a clinician please select “human upgrade/longevity” as the type of consult to get specialized biohacking clinicians! ** SPONSORS -Timeline | Head to https://www.timeline.com/dave to get 10% off your first order. -Leela Quantum Tech | Head to https://leelaq.com/DAVE for 10% off. Resources: • Dave Asprey's New Book - Heavily Meditated: https://daveasprey.com/heavily-meditated/ • IntellxxDNA Website: https://intellxxdna.com/asprey/ • 2025 Biohacking Conference: https://biohackingconference.com/2025 • Danger Coffee: https://dangercoffee.com • Dave Asprey's Website: https://daveasprey.com • Dave Asprey's Linktree: https://linktr.ee/daveasprey • Upgrade Collective – Join The Human Upgrade Podcast Live: https://www.ourupgradecollective.com • Own an Upgrade Labs: https://ownanupgradelabs.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen – Neurofeedback Training for Advanced Cognitive Enhancement: https://40yearsofzen.com Timestamps: • 00:00 – Intro • 02:00 – The Role of Genetics in Longevity • 03:37 – Gene Variants & Cognitive Health • 05:58 – Epigenetics vs. Genetics • 08:21 – Genomics & Pain Management • 09:26 – Breakthroughs in Genetic Research • 12:33 – The Future of Genomic Medicine • 14:27 – How to Use Genomic Reports • 38:25 – Mitochondria & Longevity • 42:40 – BH4 & Mental Health • 43:42 – Folinic Acid & Brain Function • 44:37 – Genomics & Autism • 46:06 – Personalized Medicine • 56:00 – APOE4 & Alzheimer's Risk • 59:44 – Genetics & Heart Health • 01:04:54 – The Future of Precision Medicine • 01:20:23 – Conclusion & Next Steps See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The EMJ Podcast: Insights For Healthcare Professionals
Onc Now: Episode 12: The Future of Breast Cancer Immunotherapy

The EMJ Podcast: Insights For Healthcare Professionals

Play Episode Listen Later Mar 5, 2025 29:18


In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Heather McArthur, Associate Professor in the Department of Medicine at University of Texas, UT Southwestern Medical Center, USA. They discuss recent advancements in breast cancer immunotherapy and the future of personalised care.  Timestamps:    00:00 - Introduction  01:20 - Transformative breakthroughs in immunotherapy  03:51 - Communicating new research to the public  05:48 - Racial disparities in cancer screenings  07:22 - Unmet needs in treating triple-negative breast cancer  11:48 - Genomic profiling and molecular pathways   13:30 - Barriers to personalised treatment plans  15:09 - Designing and conducting large-scale, international trials  19:16 - Optoacoustic imaging in cancer  22:52 - The ‘first' cell and the heterogeneity of breast tumours  25:21 – Heather's three wishes for healthcare 

GC Chat: A Genetic Counselling Podcast
S4E3: Opening the envelope

GC Chat: A Genetic Counselling Podcast

Play Episode Listen Later Mar 2, 2025 26:03


In this episode, we begin by discussing the counselling issues and interventions raised in episode 2: Countertransference. We'll then present this week's case, where the genetic counsellor experienced their first predictive testing results disclosure in neurogenetics. Support us by buying a coffee: https://buymeacoffee.com/gcchatpod Sound engineer: Shaun Allen You will find suggestions for support, our privacy statement and disclaimer, and more information about topics referenced in our discussion on our website. https://gcchatpodcast.libsyn.com/  You can find us on Instagram, Facebook and Bluesky. Join the discussion with #GCchatpodcast References mentioned in our discussion: Clark, (2010). Life as a pregnant genetic counselor. Journal of Genetic Counseling https://doi.org/10.1007/s10897-010-9283-3. Clark, (2012). Life as a pregnant genetic counselor: take two. Journal of Genetic Counseling https://doi.org/10.1007/s10897-011-9411-8. Kessler, (1992). Psychological aspects of genetic counseling. VIII. Suffering and countertransference. Journal of Genetic Counseling https://doi.org/10.1007/BF00962826. Menezes et al., (2010). “It's Challenging on a Personal Level”—Exploring the ‘Lived Experience' of Australian and Canadian Prenatal Genetic Counselors. Journal of Genetic Counseling https://doi.org/10.1007/s10897-010-9315-z Menezes, (2012). Commentary on “Life as a Pregnant Genetic Counselor: Take Two”. Journal of Genetic Counseling  https://doi.org/10.1007/s10897-011-9413-6 Menezes et al., (2013), “Taking Its Toll”: The Challenges of Working in Fetal Medicine. Birth https://doi.org/10.1111/birt.12029 Porges, (2017). The pocket guide to the polyvagal theory: the transformative power of feeling safe. USA: Norton & Company. Redlinger-Grosse, (2020). Countertransference. In Genetic Counseling Practice (eds B.S. LeRoy, P.M. Veach and N.P. Callanan). https://doi.org/10.1002/9781119529873.ch8 Rietzler, et al. (2018). Perceived Changes to Obstetric Care and the Integration of Personal and Professional Life as a Pregnant Prenatal Genetic Counselor. Journal of Genetic Counseling, https://doi.org/10.1007/s10897-018-0210-3

Mind & Matter
Short-Chain Fatty Acids, Diabetes Subtypes & Wearable HealthTech | Michael Snyder | 211

Mind & Matter

Play Episode Listen Later Mar 1, 2025 50:49


Send us a textShort Summary: Personalized health monitoring with Professor Michael Snyder, blending cutting-edge science with practical tips and actionable insights.About the guest: Michael Snyder, PhD is a Professor of Genetics at Stanford University School of Medicine. He directs the Center for Genomics and Personalized Medicine, which focuses on big data and health innovation. Snyder holds a PhD from Caltech and completed postdoctoral work at Stanford. His career has spanned yeast genomics to human health profiling. Currently, he leads research on advanced molecular and wearable technologies while spinning off companies like Q Bio to translate findings into real-world health solutions.Note: Podcast episodes are fully available to paid subscribers on the M&M Substack and everyone on YouTube. Partial versions are available elsewhere. Full transcript and other information on Substack.Episode Summary: Nick talks to Dr. Michael Snyder about transforming medicine through personalized health monitoring, leveraging tools like wearables, continuous glucose monitors, and deep molecular profiling. They explore how diet, microbiome, and genetics shape metabolic health, delving into Snyder's research on diabetes subtypes, short-chain fatty acids, and aging patterns. The conversation also covers practical technologies available today, like smartwatches and home blood tests, and their potential to catch diseases early and extend healthy lifespans.Key Takeaways:Medicine is shifting from sick care to proactive health care using comprehensive data from wearables and molecular profiling.Diabetes has many subtypes, not just type 1 or 2, and treatments like drugs or diet should match an individual's specific profile.Dietary fiber boosts gut health by producing short-chain fatty acids, which influence gene expression and may reduce leaky gut risks.Aging isn't linear—big changes spike in the 40s and 60s, varying by person (e.g., heart, kidneys, metabolism), offering chances to adjust lifestyles early.Wearables like fitness watches can detect illnesses (e.g., COVID, Lyme) days before symptoms by tracking heart rate shifts.Continuous glucose monitSupport the showAll episodes, show notes, transcripts, etc. at the M&M Substack Affiliates: Lumen device to optimize your metabolism for weight loss or athletic performance. Use code MIND for 10% off. Readwise: Organize and share what you read. Athletic Greens: Comprehensive & convenient daily nutrition. Free 1-year supply of vitamin D with purchase. KetoCitra—Ketone body BHB + potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off any subscription. MASA Chips—delicious tortilla chips made from organic corn and grass-fed beef tallow. No seed oils or artificial ingredients. Use code MIND for 20% off. For all the ways you can support my efforts

Matters Microbial
Matters Microbial #80: Do Microbes Make the Best Chemists?

Matters Microbial

Play Episode Listen Later Feb 27, 2025 59:58


Matters Microbial #80: Do Microbes Make the Best Chemists? February 27, 2025 Today, Dr. Marc Chevrette, Assistant Professor of Microbiology and Cell Science at the University of Florida, joins the #QualityQuorum to discuss how his research group can study novel metabolites and even interactions via study of microbial genomes! Dr. Chevrette reminds us all that microbes are the best chemists! Host: Mark O. Martin Guest: Marc Chevrette Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode  An overview of how quickly the field of microbial genomics has advanced. How secondary metabolites can be important to antibiosis, cell signaling, and even communication. An overview of genome mining, along with another review. The program antiSMASH that analyzes genomes for genes involved with secondary metabolites. A video describing how antiSMASH can be used to search for possible biosynthetic gene clusters. An essay about Dr. Julian Davies. An article by Dr. Davies' group suggesting that antibiotics can serve as chemical signals between microbes. The idea of “parvomics,” studying the role of small molecules in how microbes communicate and interact. A great article from Dr. Chevrette and colleagues about how to look for biosynthetic diversity using genome mining. An article by Dr. Chevrette and colleagues exploring how groups of microbes can interact in remarkable ways. Dr. Chevrette's faculty website. Dr. Chevrette's research website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

The Moos Room
Episode 283 - Beef on Dairy: Unlocking Genomics, Genetics, and Sire Secrets - UMN Extension's The Moos Room

The Moos Room

Play Episode Listen Later Feb 24, 2025 22:46


Beef on Dairy: Genomics, Genetics, and Sire SelectionIn this final episode of The Moos Room's three-part Beef on Dairy series, Brad dives into the genetics and genomics of beef-on-dairy crosses. He breaks down the results of genomic testing on 50 crossbred animals, highlighting how breed composition influences carcass traits, marbling, and growth rates.Brad explains how new genomic tools, such as Neogen's identity profile, can help farmers predict carcass weight, average daily gain, and marbling potential early in an animal's life. While the test worked well for supported breeds like Angus and Simmental, results for Charolais and other breeds were inconsistent due to database limitations.The episode also covers sire differences, showing how genetic selection significantly impacts final carcass quality. Brad discusses his own approach to selecting beef sires for dairy cows—prioritizing calving ease and ribeye area over growth rate. He emphasizes that understanding sire variability is key to optimizing beef-on-dairy performance.Finally, Brad explores how genomic testing could help feedlot management, allowing producers to sort and feed cattle based on their genetic potential, potentially increasing profitability. However, the cost-effectiveness of testing for terminal animals remains an open question.Tune in to learn how genomics is shaping the future of beef-on-dairy production!

GC Chat: A Genetic Counselling Podcast
S4E2: Countertransference

GC Chat: A Genetic Counselling Podcast

Play Episode Listen Later Feb 23, 2025 30:31


In this episode, we begin by discussing the counselling issues and interventions raised in episode 1: Ethical Conflicts. We'll then present this week's case, where the genetic counsellor encountered countertransference. Support us by buying a coffee: https://buymeacoffee.com/gcchatpod Sound engineer: Shaun Allen You will find suggestions for support, our privacy statement and disclaimer, and more information about topics referenced in our discussion on our website. https://gcchatpodcast.libsyn.com/  You can find us on Instagram, Facebook and Bluesky. Join the discussion with #GCchatpodcast References mentioned in our discussion: Crook, et al., (2022). Genetic counseling and diagnostic genetic testing for familial amyotrophic lateral sclerosis and/or frontotemporal dementia: A qualitative study of client experiences. Journal of Genetic Counseling,  https://doi.org/10.1002/jgc4.1591   Crook, et al., (2021). Patient and relative experiences and decision-making about genetic testing and counseling for familial ALS and FTD: A systematic scoping review. Alzheimer Disease & Associated Disorders https://doi.org/10.1097/WAD.0000000000000458   May & Spellecy, (2006). Autonomy, full information and the right not to know. European journal of health law, 6(2), 119-132 World Health Organisation Meeting on Ethical Issues in Medical Genetics (‎1997: Geneva, Switzerland)‎ & WHO Human Genetics Programme. (‎1998)‎. Proposed international guidelines on ethical issues in medical genetics and genetic services: report of WHO meeting on Ethical Issues in Medical Genetics. https://iris.who.int/handle/10665/63910. Vears et al., (2020). Human Genetics Society of Australasia Position Statement: Predictive and Pre-symptomatic Genetic Testing in Adults and Children. Twin Research and Human Genetics.https://doi.org/10.1017/thg.2020.51

Matters Microbial
Matters Microbial #79: How Amoebae Beat the Heat

Matters Microbial

Play Episode Listen Later Feb 20, 2025 59:13


Matters Microbial #79: How Amoebae Beat the Heat February 20, 2025 Today, Dr. Angela Oliverio, Assistant Professor in the Biology Department at Syracuse University, joins the #QualityQuorum to discuss what her research group has been learning about extremophilic single-celled eukaryotes! Host: Mark O. Martin Guest: Angela Oliverio Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode An overview of protists.   A wondrous video of the types of protists to be found seemingly everywhere. A video about amoebae and how YOU can find them.   A video about the testate amoebae mentioned in this podcast. An essay about the testate amoebae. A very old article on temperature limits to eukaryotic life. A more modern article on this topic. An article from Dr. Oliverio's group on the temperature limits to eukaryotic life. The Mullin laboratory at UCSF does remarkable visualization. Genomics and the Lawrence Livermore Laboratory. How mycoplasma move, with remarkable videos. A member of Dr. Oliverio's lab creates beautiful glass art at this Etsy shop. A wonderful local news report on Dr. Oliverio and coworker's research. A nice overview of Dr. Oliverio's research interest in extremophilic protists. An article from Dr. Oliverio's group explaining why we should all care about extremophilic eukaryotes. Dr. Oliverio's research website (and SO worth your time) Dr. Oliverio's faculty website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

The Mushroom Hour Podcast
Ep. 189: Mycota Labs - Documenting the Fungal Biodiversity of North America (feat. Dr. Stephen Russell)

The Mushroom Hour Podcast

Play Episode Listen Later Feb 17, 2025 58:31


GUEST:   https://mycota.com/   MENTIONS:   https://www.mycoportal.org/portal/taxa/index.php?taxon=274169   https://www.inaturalist.org/   http://ww.calalive.org/   MUSHROOM HOUR:   https://welcometomushroomhour.com    https://instagram.com/welcome_to_mushroom_hour   https://tiktok.com/@welcome_to_mushroom_hour   Show Music courtesy of the one and only Chris Peck: https://peckthetowncrier.bandcamp.com/   TOPICS COVERED:   Passion for Mushroom Cultivation   Wild Mushroom Identification   DNA barcoding vs. Whole Genome Sequencing   Sanger Sequencing & Nanopore Sequencing   DNA Sequencing Process from Specimen to Final DataAI & Algorithms Interpreting Genetic Data   Creating Foundational Data Sets   Unidentified Fungi All Around Us   Expanding from Indiana Across North America   Genetic Data Making Better Field Mycologists   What is a “Species”?   The Species Problem in Medicinal Mushroom Research   Becoming a Contributor to Mycota Labs Projects   Bioinformatics & Scaling Biodiversity Studies   

This Week in Health IT
Keynote: Unlocking New Standards of Care through Genomics with Sue Schade and Albert Oriol

This Week in Health IT

Play Episode Listen Later Feb 13, 2025 31:23 Transcription Available


February 13, 2025: Sue Schade, Principal at StarBridge Advisors, interviews Albert Oriol, CIO of Rady Children's Hospital, to discuss how genomics and technology partnerships are transforming pediatric care. How can precision medicine and newborn screening change the trajectory of a child's life? What role does IT play in addressing workforce burnout and cybersecurity risks? And how do visionary leaders balance cutting-edge technology with operational demands? Key Points:05:19 Advancements in Precision Medicine15:08 Albert Oriol's Career Journey18:29 IT Collaboration22:52 Remote Work and Workforce Flexibility27:04 Work-Life Balance and Personal Well-beingSubscribe: This Week HealthTwitter: This Week HealthLinkedIn: This Week HealthDonate: Alex's Lemonade Stand: Foundation for Childhood Cancer

Science Friday
Strain Of Bird Flu Discovered In California | Understanding Bipolar Disorder Through The Genome

Science Friday

Play Episode Listen Later Jan 31, 2025 24:21


The outbreak of H5N9 avian influenza occurred at a California duck farm in November 2024. Also, new research pinpoints 298 parts of the genome associated with higher risk of bipolar disorder. This could lead to better treatments.Another Strain Of Bird Flu Discovered In CaliforniaThis week, the World Organization for Animal Health reported that it had been notified by the USDA that a November outbreak of highly pathogenic avian influenza on a California duck farm was caused by a strain not before seen in the United States: H5N9. The dominant bird flu strain circulating currently, H5N1, has led to massive culling of bird flocks, has infected dairy cattle, and has killed almost 500 people around the world since 2003. The US reported its first human death from bird flu earlier this month.Experts stressed that the new strain did not itself appear to be an immediate human threat. But the rise of a new strain is troubling and points to the risk of a viral phenomenon known as “reassortment,” in which different viruses mingled in a host can sometimes exchange bits of viral code, forming new strains.SciFri's Charles Bergquist joins Flora Lichtman to talk about H5N9 and other stories from the week in science, including a spacewalk that was meant to include a search for microbes on the outside of the International Space Station, a possible positive side effect of scratching an itch, and the discovery of 66 million-year-old fossilized vomit.Understanding Bipolar Disorder Through The GenomeBipolar disorder is one of the most common mental illnesses—it affects an estimated 40 million people worldwide, about 2.8% of the population. Bipolar disorder can cause extreme mood swings, and be debilitating without treatment.In an effort to untangle the mysteries of where bipolar disorder originates, researchers studied the genomes of more than 40,000 people with the condition. When comparing these genomes to those of people without bipolar disorder, the researchers were able to pinpoint 298 different parts of the genome associated with the mental illness. With this better understanding of the genome, better, more targeted treatments for bipolar disorder may be possible.Joining Flora to talk about this research is Dr. Niamh Mullins, assistant professor of psychiatric genomics at the Icahn School of Medicine at Mount Sinai in New York.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Burn it Nutrition Podcast
Ep170: Precision Medicine | How Genomics and Personalized Healthcare Can Transform Your Life with Dr. Matthew Dawson

Burn it Nutrition Podcast

Play Episode Listen Later Jan 23, 2025 35:36


●     Genomics and Personalized Medicine ●       Get a Doctor that will work with YOU ●       Genetics vs Genomics ●       Do you know your biological age? ●       How personal data becomes healthcare ●       Sick care vs True Health care ●       Ai and epigenetics ●       And so much more!   Links mentioned in this episode! Show notes page: https://burnitnutrition.com/podcast170/ . . Dry Farm Wines - Zero Sugar & Keto Friendly! Get a extra bottle for 1 Penny with your first order! www.Dryfarmwines.com/BURNIT . .  LMNT – Get a free sample pack with your first order – https://drinklmnt.com/burn . . BiOptimizers - Get Magnesium Breakthrough and get 10% discount with code burnit   - http://bioptimizers.com/burnit . . Learn more about Dr. Matthew Dawson: Website: https://www.wildhealth.com/   . . Podcast Shop Page for Best Deals at https://burnitnutrition.com/shop  . Leave me a rating & review on Apple Podcasts: https://itunes.apple.com/us/podcast/burn-it-nutrition-podcast/id1195955730?mt=2  . Follow Joseph Navarro on Instagram under @BurnitNutrition . Follow Joseph Navarro on Facebook under @BurnitNutrition . Thank You for Listening!! Please share this episode! Be the one who helps spark a transformation in your family! Feedback to share? Send email to info@BurnitNutrition.com Subscribe! Don't miss another episode! Notice of Sponsorship Affiliate Disclosure with BiOptimizers, LMNT, & Dry Farm Wines  Fair Use Disclaimer The following podcast episode contains audio clips that are used under the doctrine of fair use as defined by United States copyright law. These clips are used for purposes of commentary, criticism, news reporting, teaching, scholarship, and research. All rights to the original audio content remain with the respective copyright holders. This use is not intended to infringe upon their rights, but to enhance the discussion and understanding of the topic at hand. Please read the full medical disclaimer  burnitnutrition.com/medical-disclaimer/

Razib Khan's Unsupervised Learning
David Mittelman: pushing the genomic frontier in 2024

Razib Khan's Unsupervised Learning

Play Episode Listen Later Jan 23, 2025 56:41


  Three years ago David Mittelman came on Unsupervised Learning to talk about emerging possibilities on the frontiers of genomics, and his new startup at the time, Othram. Since then, Othram's work has been featured widely in the media, including in a Law & Order episode, and the firm has solved thousands of unsolved cases, with nearly 500 public. For over a decade, Mittelman has been at the forefront of private-sector genomics research. He trained at Baylor College of Medicine and was previously faculty at Virginia Tech. Razib and Mittelman discuss the changes that the rapid pace of genomic technology has driven in the field of genetics, from the days a $3 billion dollar draft human genome in the year 2000 to readily available $200 consumer genomes in 2024. One consequence of this change has been genetics' transformation into information science, and the dual necessities of increased data storage and more powerful, incisive data analysis. Genomics made information acquisition and analysis so easy across the research community that it allowed for the pooling of results and discoveries in big databases. This has pulled genetics out of the basic science lab and allowed it to expand into an enterprise with a consumer dimension. Mittelman also discusses the improvements and advances in DNA extraction and analysis techniques that allow companies like his to now glean insights from decades-old samples, with bench sciences operating synergistically with computational biology. Razib and Mittelman talk about how he has helped solve hundreds of cold cases with new technology, in particular, at the intersection between new forensic techniques and both whole-genome sequencing and public genetic databases. They also discuss the future of genetics, and how it might touch our lives through healthcare and other domains, passing from inference to fields like genetic engineering